Bortezomib-Induced Skin Eruption in Patient with Newly Diagnosed Multiple Myeloma under VRd Regime: A Case Report

The proteasome inhibitor bortezomib is used to treat various hematological cancers. It is currently included in the standard of care for individuals receiving their first line treatment for a recently diagnosed multiple myeloma. Generally well tolerated, bortezomib has been linked to a number of side effects. In this instance, a reticular eruption that developed at the site of a subcutaneous bortezomib administration in a 45-year-old male patient with recently diagnosed multiple myeloma is described along with histological confirmation. After a skin biopsy, it was shown that the perivascular of lymphocytes and eosinophils admixed with neutrophils at dermis with unremarkable hypodermis. The patient responded well to betamethasone dipropionate 0.05% cream treatment.